North America Cancer Biomarkers Market – Industry Trends and Forecast to 2027

  • Medical Devices
  • Upcoming Report
  • Jan 2020
  • North America
  • 150 Pages
  • No of Tables: 30
  • No of Figures: 50

North America Cancer Biomarkers Market, By Type (Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Non-Hodgkin’s Lymphoma, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Blood Cancer, Ovarian Cancer, Liver Cancer, Stomach Cancer, Kidney Cancer, Other Cancer Types), By Technology (Omics Technologies, Imaging Technologies, Immunoassays, Cytogenetics, Bioinformatics), By Application (Diagnostics, Research and Development, Prognostics, Risk Assessment, Others), By Country (U.S., Canada, Mexico), Industry Trends and Forecast to 2027

North America Cancer Biomarkers Market

Market Analysis and Insights: North America Cancer Biomarkers Market

Cancer Biomarkers Market is expected to grow in the forecast period from 2020 to 2027. Data Bridge Market Research analyses the market for USD 10.17 billion by 2027, growing at a CAGR of 11.13% over the above-mentioned forecast period. The growth of North America cancer biomarkers market is attributed to growing usage of cancer biomarkers in drug discovery and development.

A biomarker for cancer refers to a tissue or device that indicates the presence of cancer in the body. A biomarker may be a material secreted by a tumor or a clear response of the body to the presence of cancer. Genetic, glycomic, proteomic, epigenetic and biochemical biomarkers can be used for cancer diagnosis, prognosis and epidemiology. Ideally, such biomarkers may be tested in non-invasively derived biofluids such as blood and serum.

Cancer biomarkers may also be helpful in the development of a specific diagnosis. This is particularly the case when it is necessary to determine whether tumors are of a primary or metastatic nature. In order to allow this differentiation, scientists must track chromosome changes in cells located at the primary tumor site against those present at the secondary location. If the alterations align, the secondary tumor may be classified as metastatic, whereas if the alterations vary, the secondary tumor may be identified as a separate primary tumor.

Rising incidences of cancer along with increasing research on cancer biomarkers are some of the key drivers that will impact this markets growth in the forecast period of 2020 to 2027. Technical issues related to sample collection and storage is one of the major factors which restrain this market growth.

This cancer biomarkers market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cancer biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

North America Cancer Biomarkers Market Scope and Market Size

Cancer biomarkers market is segmented on the basis of type, cancer type, technology and application. Such categories allow you to evaluate progress in different niche exchanges and consumer strategy approaches and define the main areas of operation, as well as help you uncover the main difference between your target markets.

  • Cancer biomarkers are mechanisms or substances that demonstrate cancers of the body. In response to cancer, biomarkers may be produced either by the cancer tissue itself or by other cells in the body. They may be present in the blood, pulse, urine, tumor, or other tissues or fluids of the body. We improve cancer detection and facilitate high-speed, non-invasive treatment with genomics and proteomics.
  • Based on the type, North America cancer biomarkers market is mainly segmented into protein biomarkers, genetic biomarkers and other cancer biomarkers. North America cancer biomarkers market based on genetic biomarkers is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer and leukemia.
  • Based on the cancer type, North America cancer biomarkers market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, non-Hodgkin’s lymphoma, melanoma, leukemia, thyroid cancer, bladder cancer, blood cancer, ovarian cancer, liver cancer, stomach cancer, kidney cancer and other cancer types.
  • Based on the technology, North America cancer biomarkers market is divided into omics technologies, imaging technologies, immunoassays, cytogenetics and bioinformatics. North America cancer biomarkers market is further segmented on the basis of omics technologies into proteomics, genomics and other omics technologies. Imaging technologies is further sub-segmented into ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and mammography. Cytogenetics segments is sub-segmented into in-situ hybridization (ISH) and other cytogenetics-based tests.
  • Based on the application, North America cancer biomarkers market is segmented into diagnostics, research and development, prognostics, risk assessment and others.

Cancer Biomarkers Market Country Level Analysis

Cancer biomarkers market is analysed and market size information is provided by country, type, cancer type, technology and application as referenced above. The countries covered in North America cancer biomarkers market report are U.S., Canada and Mexico.

The country section of the artificial organs market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

North America cancer biomarkers market report also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for North America cancer biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the North America cancer biomarkers market. The data is available for the historic period of 2010 to 2018.

Competitive Landscape and Cancer Biomarkers Market Share Analysis

North America cancer biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to cancer biomarkers market.

The major players of North America cancer biomarkers market covered in the report are Abbott, DiagnoCure Inc, Affymetrix, Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Quest Diagnostics Inc., Merck & Co. Inc., Hologic, Inc., BD, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Genomic Health, Inc., bioMérieux SA, Myriad Genetics and Biodesix among other regional and domestic players.

In November 2019, Biodesix has acquired Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States to extend the diagnostic portfolio of blood-based lung cancer. Biodesix is a pioneer in the creation and application of blood-based therapeutic approaches for lung cancer. The initiation of the purchase of Oncimmune in the U.S. was emblematic of our continued growth and service across the spectrum of patient lung treatment.

The market share data in this report is available only for North America cancer biomarkers market.  DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available : North America Cancer Biomarkers Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19